婴儿肾脏替代治疗使用Carpediem:ICONIIC学习网络的多中心观察性队列研究
该多中心观察性研究评估了美国首个婴儿专用连续肾脏替代治疗(CRRT)平台Carpediem在婴儿中的适应症与结局。研究纳入67名婴儿、93个治疗疗程,主要适应症为终末期肾病(ESKD,54%)和急性肾损伤(43%)。ESKD患儿出院存活率为67%,非ESKD患儿为60%,总体CRRT存活率超过60%。
要点
- Carpediem在婴儿中CRRT出院存活率ESKD为67%、非ESKD为60%。
- 主要适应症为ESKD桥接透析(54%)和急性肾损伤(43%)。
- ESKD患儿首次治疗中位年龄18天、干体重2.6kg,非ESKD为32天、3.4kg。
核心结论
- 在美国使用Carpediem进行CRRT的婴儿中,出院存活率超过60%。
- 超过一半的治疗适应症为ESKD,作为透析的桥接。
研究设计与样本
- 多中心、回顾性和前瞻性观察性研究,通过ICONIIC学习网络开展。
- 数据来自首批使用Carpediem的四家美国中心。
- 共67名婴儿接受93个治疗疗程,使用1538个滤器和112根血管通路导管。
- 治疗疗程定义为间隔≤72小时的连续CRRT操作。
- 婴儿队列按CRRT适应症分为ESKD(CRRT作为腹膜透析桥接)和非ESKD(所有其他适应症)。
主要发现
- 主要CRRT适应症为ESKD 36例(54%),急性肾损伤43%。
- ESKD队列首次治疗中位年龄18天(IQR:6,81),干体重2.6kg(IQR:2.4,3.1)。
- 非ESKD队列首次治疗中位年龄32天(IQR:9,90),干体重3.4kg(IQR:3.2,4.5)。
- ESKD中位治疗疗程持续时间12天(IQR:3,24),非ESKD为4天(IQR:1,13)。
- 出院存活率ESKD为67%,非ESKD为60%。
临床怎么用
- Carpediem可作为婴儿专用CRRT平台用于ESKD桥接透析及急性肾损伤等适应症。
- 临床中应关注ESKD婴儿较长的治疗疗程和较低的干体重。
局限性
- 研究为观察性设计,仅纳入首批四家美国中心,可能存在选择偏倚。
- 样本量较小(67名婴儿),结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate indications and outcomes of Carpediem as the first infant-specific continuous renal replacement therapy (CRRT) platform available for clinical use in the US. STUDY DESIGN: A multicenter, retrospective, and prospective observational study was conducted through the "Improving CRRT Outcomes in Neonates and Infants through Interdisciplinary Collaboration" Learning Network. Data were collected from the first four US centers utilizing Carpediem. A treatment course was defined as sequential CRRT procedures separated by ≤72 hours. Infant cohorts were categorized by CRRT indication: end-stage kidney disease (ESKD) (ie, CRRT as a bridge to peritoneal dialysis) and non-ESKD (all other indications). RESULTS: Sixty-seven infants underwent 93 treatment courses using 1538 filters and 112 vascular access catheters. The primary indication for CRRT was ESKD in 36 (54%) and acute kidney injury in 43%. Median age at first treatment was 18 (IQR: 6, 81) days, and dry weight was 2.6 (IQR: 2.4, 3.1) kg for the ESKD cohort and 32 (IQR: 9, 90) days and 3.4 (IQR: 3.2, 4.5) kg for the non-ESKD cohort. Median treatment course duration was 12 (IQR: 3, 24) days for ESKD compared with 4 (IQR: 1, 13) days for non-ESKD infants. Survival for hospital discharge was 67% in ESKD and 60% in non-ESKD. CONCLUSIONS: In this US cohort study, CRRT survival in infants treated with Carpediem exceeds 60%. More than one-half of the treatment indications were for ESKD as a bridge to dialysis.
引用
- Slagle CL, Vuong KT, Krallman KA, et al. Infant Renal Replacement Therapy Using Carpediem: A Multicenter Observational Cohort Study from the ICONIIC Learning Network. J Pediatr. 2025. PMID: 41016463. doi:10.1016/j.jpeds.2025.114838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。